Literature DB >> 8946196

Detection of 11q13 amplification as the origin of a homogeneously staining region in small cell lung cancer by chromosome microdissection.

J Xu1, T Tyan, E Cedrone, N Savaraj, N Wang.   

Abstract

Chromosomal homogeneous staining region (hsr), which is a cytogenetic indication of gene amplification, was found in the pleural effusion (BHII) of a patient with small cell lung cancer (SCLC) after failure of multiple drug treatments. Amplification of band 11q13 was identified as the origin of the hsr by means of chromosomal microdissection combined with G-banding, DNA amplification by polymerase chain reaction, and fluorescence in situ hybridization (micro-FISH). In situ hybridization with the biotin-labeled DNA probe generated from the hsrs of BHII to the cell line BHI, which was established from the lymph node metastasis prior to chemotherapy, revealed the preexistence of 11q13 amplification. This ruled out the possibility of therapeutic induction of the 11q13 amplification. However, the hsr-bearing marker chromosomes were identified by the micro-FISH approach as der(21)(Xqter-->Xq24::hsr(11)(q13)::21p11-->21qter+ ++) in BHII but as der(11)t(3;11)(q21;q13)hsr(11)(q13) in BHI. This suggests that 11q13 DNA sequence amplification may occur first and is then followed by various types of structural rearrangements. FISH analysis with INT2/FGF3 and HST1/FGF4 probes revealed that these protooncogenes were coamplified in the hsrs of BHI and BHII. The results obtained suggest that 11q13 amplification and the successive structural rearrangement may play an important role in the progression of the disease and its therapeutic response.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8946196     DOI: 10.1002/(SICI)1098-2264(199611)17:3<172::AID-GCC5>3.0.CO;2-1

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  14 in total

1.  The relationship of thioredoxin-1 and cisplatin resistance: its impact on ROS and oxidative metabolism in lung cancer cells.

Authors:  Medhi Wangpaichitr; Elizabeth J Sullivan; George Theodoropoulos; Chunjing Wu; Min You; Lynn G Feun; Theodore J Lampidis; Macus T Kuo; Niramol Savaraj
Journal:  Mol Cancer Ther       Date:  2012-01-16       Impact factor: 6.261

2.  Overexpression of Rsf-1 correlates with poor survival and promotes invasion in non-small cell lung cancer.

Authors:  Xiuwei Zhang; Lin Fu; Dongwei Xue; Xiupeng Zhang; Fengxia Hao; Lingling Xie; Jiani He; Junda Gai; Yuhui Liu; Hongtao Xu; Qingchang Li; Enhua Wang
Journal:  Virchows Arch       Date:  2017-03-13       Impact factor: 4.064

3.  Intrinsically lower AKT, mammalian target of rapamycin, and hypoxia-inducible factor activity correlates with increased sensitivity to 2-deoxy-D-glucose under hypoxia in lung cancer cell lines.

Authors:  Medhi Wangpaichitr; Niramol Savaraj; Johnathan Maher; Metin Kurtoglu; Theodore J Lampidis
Journal:  Mol Cancer Ther       Date:  2008-06       Impact factor: 6.261

4.  N',N'-Dimethyl-N',N'-bis(phenylcarbonothioyl) Propanedihydrazide (Elesclomol) Selectively Kills Cisplatin Resistant Lung Cancer Cells through Reactive Oxygen Species (ROS).

Authors:  Medhi Wangpaichitr; Chunjing Wu; Min You; Johnathan C Maher; Vy Dinh; Lynn G Feun; Niramol Savaraj
Journal:  Cancers (Basel)       Date:  2009       Impact factor: 6.639

5.  Association between CCND1 G/A870 polymorphism, allele-specific amplification, cyclin D1 expression, and survival in esophageal and lung carcinoma.

Authors:  Vanita K Gupta; Andrew Feber; Liqiang Xi; Arjun Pennathur; Maoxin Wu; James D Luketich; Tony E Godfrey
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531

6.  Inhibition of mTOR restores cisplatin sensitivity through down-regulation of growth and anti-apoptotic proteins.

Authors:  Medhi Wangpaichitr; Chunjing Wu; Min You; M T Kuo; Lynn Feun; Theodore Lampidis; Niramol Savaraj
Journal:  Eur J Pharmacol       Date:  2008-06-12       Impact factor: 4.432

7.  Targeting the Kynurenine Pathway for the Treatment of Cisplatin-Resistant Lung Cancer.

Authors:  Dan J M Nguyen; George Theodoropoulos; Ying-Ying Li; Chunjing Wu; Wei Sha; Lynn G Feun; Theodore J Lampidis; Niramol Savaraj; Medhi Wangpaichitr
Journal:  Mol Cancer Res       Date:  2019-10-18       Impact factor: 5.852

8.  Genomic profiles in stage I primary non small cell lung cancer using comparative genomic hybridization analysis of cDNA microarrays.

Authors:  Feng Jiang; Zhengnan Yin; Nancy P Caraway; Ruiyun Li; Ruth L Katz
Journal:  Neoplasia       Date:  2004 Sep-Oct       Impact factor: 5.715

9.  Upregulation of miR-31* is negatively associated with recurrent/newly formed oral leukoplakia.

Authors:  Wen Xiao; Zhe-Xuan Bao; Chen-Yang Zhang; Xiao-Yun Zhang; Lin-Jun Shi; Zeng-Tong Zhou; Wei-Wen Jiang
Journal:  PLoS One       Date:  2012-06-18       Impact factor: 3.240

10.  Overcoming cisplatin resistance by mTOR inhibitor in lung cancer.

Authors:  Chunjing Wu; Medhi Wangpaichitr; Lynn Feun; Marcus Tien Kuo; Carlos Robles; Theodore Lampidis; Niramol Savaraj
Journal:  Mol Cancer       Date:  2005-07-20       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.